Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) — Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative...
Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma Waltham, MA – September 5, 2017 – Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on...
Recent Comments